Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07196644 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
A Phase 2 study of Solid Tumors Harboring MET Amplification, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT07196644 is a Phase 2 study of Solid Tumors Harboring MET Amplification that is actively recruiting participants, run by AbbVie. The registered enrollment target is 125 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT07196644, a Phase 2 study of Solid Tumors Harboring MET Amplification, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of locally advanced or metastatic solid tumors that harbor MET amplification. This study will have 1 arm where participants will receive telisotuzumab adizutecan. Approximately 125 participants 12 years of age or older. with solid tumors harboring MET amplification will be enrolled in the study in up to 55 sites around the world. Participants will receive intravenous (IV) telisotuzumab adizutecan, as part of the 61.5 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions Studied
Interventions
- DRUG Telisotuzumab Adizutecan
Study Locations (20)
California
- City of Hope National Medical Center /ID# 275613 - Duarte
- Valkyrie Clinical Trials /ID# 275547 - Los Angeles
Illinois
- Northwestern University Feinberg School of Medicine /ID# 276436 - Chicago
- University of Chicago Medical Center /ID# 275342 - Chicago
Texas
- The University of Texas MD Anderson Cancer Center /ID# 275663 - Houston
- South Texas Accelerated Research Therapeutics (START) /ID# 276608 - San Antonio
Tel Aviv
- The Chaim Sheba Medical Center /ID# 274342 - Ramat Gan
- Tel Aviv Sourasky Medical Center /ID# 274344 - Tel Aviv
Other
- Hadassah Medical Center-Hebrew University /ID# 274343 - Jerusalem
- Rabin Medical Center. /ID# 274341 - Petah Tikva
Connecticut
- Yale University School of Medicine /ID# 275978 - New Haven
Florida
- Florida Cancer Specialists - North /ID# 277137 - St. Petersburg
Michigan
- START Midwest /ID# 276603 - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-10-29 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07196644
The ClinicalTrials.gov registry entry for NCT07196644 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors Harboring MET Amplification appearing as the primary indexed condition, and to 1 intervention - of which Telisotuzumab Adizutecan is the first listed.
NCT07196644 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT07196644 about?
NCT07196644 is a clinical study titled "A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan". Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of ...
What is the current status of trial NCT07196644?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2025-10-29. Estimated completion is 2030-12.
What conditions does trial NCT07196644 study?
This clinical trial studies the following conditions: Solid Tumors Harboring MET Amplification.
What interventions are being tested in trial NCT07196644?
The interventions under investigation include: Telisotuzumab Adizutecan (DRUG).
Who is sponsoring clinical trial NCT07196644?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07196644 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.